GlassScriptPhysician profile
Katherine Roose
NPI 1821547985
$787.15
in general payments reported to CMS, 2019-2025
11 companies · $204 in 2025
The $204 reported for 2025 was more than what 75% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $59.88 · 2022: $102 · 2023: $272 · 2024: $149 · 2025: $204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $626.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $625.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $182.06 | 2022-2024 | Jornay Pm |
| Sanofi Pasteur INC. | $135.97 | 2023-2025 | |
| Corium, LLC | $85.18 | 2023-2024 | Azstarys |
| Sanofi-Aventis U.S. LLC | $66.75 | 2024-2025 | |
| Glaxosmithkline, LLC. | $64.70 | 2021-2023 | Bexsero |
| Alk-Abello, INC | $54.70 | 2024-2025 | Grastek, Ragwitek, Odactra |
| Collegium Pharmaceutical, INC. | $50.46 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $49.23 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $48.16 | 2025 | Qelbree |
| Pfizer INC. | $27.83 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $22.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Roose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.